As you may have heard, SEKISUI XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” for its CryostaX® hepatocytes. The single-freeze preparation process minimizes cryoinjury, promoting high viability, cell yield and enzymatic activity for long-term consistent test results. Additionally, the resulting “pellets” do not require thawing to be pooled or used. CryostaX® donors can be selected individually or custom pooled at no additional cost from over 200 options for specific enzyme activities, yield, pool size or donor BMI, disease state, age, ethnicity, gender, substance use, serology, etc. Lots are available for suspension or plating.
The announcement also included several other important updates, such as the implementation of technology and methodology improvements over the last year which resulted in 20-40% higher cell yield and almost 10% higher viability. Furthermore, the company renegotiated its donated liver contract for access to 3.5 times more livers, allowing the selection of higher quality tissue and specific demographics. SEKISUI XenoTech also began providing certificates of quality and sterility for its hepatocyte media…
Learn more about:
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback